

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Relugolix with oestradiol and norethindrone acetate for treating uterine fibroids**

**Batch 76**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop), and, if so, what are they?

Relugolix should be available to all eligible people with uterine fibroids, which may include transgender men or non-binary people.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider all people that are eligible for treatment when making recommendations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope have been made. The population in the draft scope and final scope refers to people with uterine fibroids and therefore includes all eligible people.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Technology Appraisals: Scoping  
Equality impact assessment for the single technology appraisal of relugolix with oestradiol and norethindrone acetate for treating uterine fibroids

No.

**Approved by Associate Director (name):** Ross Dent

**Date:** 21/04/2021